Cristal and iTeos announce strategic partnership for the development of immuno-­oncology candidates

Initial goal is to determine treatment efficacy of iTeos’ immuno-­oncology drug candidates. Option for iTeos to license Cristal’s proprietary nanotechnology platform for development of up to three immuno-­oncology therapeutic candidates.

Maastricht,  The  Netherlands  and  Gosselies,  Belgium  –  December  7th,  2016  –  Cristal  Therapeutics,  a  Dutch privately-­held life sciences company developing novel nanomedicines against cancer and other diseases  and  iTeos  Therapeutics  SA,  a  Belgian  privately-­‐held  biotechnology  company  applying  its  expertise in translational tumor immunology to the development of novel cancer immunotherapies, today  announced  a  strategic  partnership  for  the  discovery,  development  and  commercialization  of  optimized immuno anti-­cancer drug candidates, using Cristal Therapeutics’ medicinal nanotechnology CriPec® platform.

The  initial  goal  of  this  partnership  is  to  determine  the  therapeutic  efficacy  of  targeted  drugs  using  Cristal’s CriPec® application in iTeos’ preclinical models which have been proven to be predictive in combinations of several immune activators -­‐ such as IDO1 and TDO2 -­ with checkpoint inhibitors. iTeos has an option to license Cristal’s proprietary nanotechnology platform to support the development and commercialization of up to three of its immune tumor-­‐targeting programs.

CriPec®, a proprietary nanotechnology platform, consists of tuneable polymers and biodegradable drug linkers  that  allow  for  the  rational  design  and  straightforward  manufacturing  of  custom-­‐made  nanomedicines.  Applying  the  CriPec®  platform  -­  drugs  entrapped  in  CriPec®  nanoparticles  -­  results  in immuno  nanomedicines  with  a  superior  product  profile  as  compared  to  the  native  drug  molecule.  CriPec® nanoparticles improve the disposition of thousands of drug molecules per particle and allow the controlled  release  of  these  molecules  specifically  at  the  target  site.  This  results  in  an  improved  therapeutic efficacy and tolerability.

Joost Holthuis, Cristal Therapeutics’ CEO, commented:

“This partnership with iTeos allows us to assess and demonstrate the application of our CriPec® nanoparticles, specifically in  the area of novel immuno-­oncology therapies. We are focused on  applying  our  nanomedicine  platform  to  several  promising  oncology  indications,  some  of  which will be evaluated for the iTeos’ development pipeline.”

Michel Detheux, , iTeos’ CEO, added:

“We  are  very  pleased  to  enter  into  this  partnership  with  an  emerging  clinical-­stage  nanomedicine platform company. Cristal has a strong and experienced management team, and has  demonstrated  the  capability  to  quickly  develop  valuable  therapeutic  programs.  We  look  forward to applying their platform to some of our drug candidates. We believe it has particular potential in the evolving area of causing so-­called “cold tumors” – which are less responsive to checkpoint inhibitors -­ to become susceptible to various immuno­-oncology therapies.”

About Cristal Therapeutics

Maastricht,  The  Netherlands  based  Cristal  Therapeutics,  is  a  privately-­held  life  sciences  company  developing  novel  nanomedicines  against  cancer  and  other  diseases,  by  using  its  patented  CriPec® platform.  CriPec®  transforms  drugs  into  polymeric  nanoparticles  via  an  innovative  process.  These  nanoparticles provide improved distribution throughout the body. The substantial improvement of the efficacy and safety of the drugs entrapped in CriPec® nanoparticles has been demonstrated in several preclinical disease models. Cristal Therapeutics’ products in development are primarily aimed at treating patients  suffering  from  cancer  but  offer  also  opportunities  for  the  treatment  of  chronic  inflammatory  diseases. CriPec® docetaxel is the most advanced product candidate, and is under clinical evaluation for the treatment of solid tumors. For more information please visit

About iTeos Therapeutics S.A.

Based  in  Gosselies,  Belgium,  iTeos,  a  spin-­off  of  Ludwig  Cancer  Research  (LICR)  and  de  Duve  Institute  (UCL),  is  focused  on  expanding  the  benefits  of  immunotherapy  for  cancer patients.  The  company  is developing a proprietary pipeline targeting A2A, immune checkpoints and non-­immunogenic tumors.  It has licensed its IDO1 program, now in Phase 1 development, to Pfizer. iTeos’ competitive edge is in the combination of expertise in drug discovery and translational tumor immunology. The company uses a unique platform to identify rational combinations of immunotherapies and novel targets. The company is supported in part by the Walloon Region of Belgium and the FEDER (European Fund for Economic and Regional Development). For more information please visit


Joost Holthuis, CEO
Cristal Therapeutics
+ 31 43 388 5868

Michel Detheux, CEO
iTeos therapeutics
+32 71 919 933

For iTeos Therapeutics:

Sarah McCabe
Stern Investor Relations, Inc. + 1 212 362-­‐1200

Jonathan Birt, Mathew Neal, Hendrik Thys
Consilium Strategic Communications
+44 2 037 095 700

For Cristal Therapeutics:

LifeSpring Life Sciences Communication Leon Melens
+31 6 538 16 427